{"id":39527,"date":"2025-08-18T14:55:48","date_gmt":"2025-08-18T06:55:48","guid":{"rendered":"https:\/\/flcube.com\/?p=39527"},"modified":"2025-08-18T14:55:49","modified_gmt":"2025-08-18T06:55:49","slug":"iregene-therapeutics-nouvneu001-receives-fda-fast-track-designation-for-parkinsons-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39527","title":{"rendered":"iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy"},"content":{"rendered":"\n

China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation also allows for an expanded scope of application for other compassionate use cases. This marks the world’s first FTD for an off-the-shelf iPSC-derived Parkinson’s cell therapy product.<\/p>\n\n\n\n

Product Overview<\/strong>
NouvNeu001 is a Class 1 biologic developed entirely by iRegene Therapeutics. It is a chemically induced human dopaminergic neuron precursor. Through chemical induction, the product achieves high-purity neural subtype reconstruction and functional optimization. After transplantation, it forms connections with existing neurons in the body and enhances cellular secretion functions, thereby improving original lesions and achieving a comprehensive therapeutic effect.<\/p>\n\n\n\n

Regulatory Milestone<\/strong>
This FTD approval follows the Special Exemption the product received from the FDA in March 2024. The designation reflects the FDA’s recognition of the potential of NouvNeu001 to address significant unmet medical needs in Parkinson’s disease treatment.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has…<\/p>\n","protected":false},"author":1,"featured_media":39529,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,1218],"class_list":["post-39527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-iregene-therapeutics"],"yoast_head":"\niRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation also allows for an expanded scope of application for other compassionate use cases. This marks the world's first FTD for an off-the-shelf iPSC-derived Parkinson's cell therapy product.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39527\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy\" \/>\n<meta property=\"og:description\" content=\"China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation also allows for an expanded scope of application for other compassionate use cases. This marks the world's first FTD for an off-the-shelf iPSC-derived Parkinson's cell therapy product.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39527\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T06:55:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-18T06:55:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy\",\"datePublished\":\"2025-08-18T06:55:48+00:00\",\"dateModified\":\"2025-08-18T06:55:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1805.webp\",\"keywords\":[\"Cell-therapy\",\"iRegene Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39527#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39527\",\"name\":\"iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1805.webp\",\"datePublished\":\"2025-08-18T06:55:48+00:00\",\"dateModified\":\"2025-08-18T06:55:49+00:00\",\"description\":\"China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation also allows for an expanded scope of application for other compassionate use cases. This marks the world's first FTD for an off-the-shelf iPSC-derived Parkinson's cell therapy product.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39527\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1805.webp\",\"width\":1080,\"height\":608,\"caption\":\"iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39527#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy - Insight, China's Pharmaceutical Industry","description":"China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation also allows for an expanded scope of application for other compassionate use cases. This marks the world's first FTD for an off-the-shelf iPSC-derived Parkinson's cell therapy product.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39527","og_locale":"en_US","og_type":"article","og_title":"iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy","og_description":"China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation also allows for an expanded scope of application for other compassionate use cases. This marks the world's first FTD for an off-the-shelf iPSC-derived Parkinson's cell therapy product.","og_url":"https:\/\/flcube.com\/?p=39527","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-18T06:55:48+00:00","article_modified_time":"2025-08-18T06:55:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39527#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39527"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy","datePublished":"2025-08-18T06:55:48+00:00","dateModified":"2025-08-18T06:55:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39527"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39527#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1805.webp","keywords":["Cell-therapy","iRegene Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39527#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39527","url":"https:\/\/flcube.com\/?p=39527","name":"iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39527#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39527#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1805.webp","datePublished":"2025-08-18T06:55:48+00:00","dateModified":"2025-08-18T06:55:49+00:00","description":"China-based iRegene Therapeutics announced on August 15, 2025, that its self-developed injectable product, NouvNeu001, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation also allows for an expanded scope of application for other compassionate use cases. This marks the world's first FTD for an off-the-shelf iPSC-derived Parkinson's cell therapy product.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39527#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39527"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39527#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1805.webp","width":1080,"height":608,"caption":"iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation for Parkinson's Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39527#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"iRegene Therapeutics’ NouvNeu001 Receives FDA Fast Track Designation for Parkinson’s Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39527"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39527\/revisions"}],"predecessor-version":[{"id":39530,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39527\/revisions\/39530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39529"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}